Latest From Quidel Corp.
The disruptive medtech M&A of recent years was not matched in the past year for volume, but there were isolated outbreaks of major activity, as shown in our company rankings.
Timothy Stenzel brings experience developing and commercializing new molecular diagnostics, including companion tests, and running a clinical laboratory to his new role as director of US FDA's Office of In Vitro Diagnostics and Radiological Health.
Third-quarter device financing at $2.38 billion – almost half of that amount from CooperSurgical's $1.1 billion bridge loan – was double the Q2 total, while device acquisitions showed a steep decrease at $3.38 billion versus Q2's $33.4 billion. Diagnostics fundraising also was up in the third quarter, reaching $2.4 billion (a 133% increase over Q2) mostly from Thermo Fisher Scientific's $1.5 billion follow-on offering, which accounted for 63% of the total. In line with the previous quarter's $1.7 billion in M&A, Q3 diagnostics acquisitions had an aggregate value of $1.8 billion, led by Konica Minolta's $1 billion buy of Ambry Genetics.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced July 2017.
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
- Therapeutic Drug Monitoring
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Quidel Corp.
- Senior Management
Douglas C Bryant, Pres. & CEO
Randall J Steward, CFO
Werner T Kroll, PhD, SVP, R&D
Robert J Bujarski, SVP, Bus. Dev. & General Counsel
Scott M McLeod, SVP, Operations
- Contact Info
Phone: (858) 552-1100
12544 High Bluff Dr., Ste. 200
San Diego, CA 92130
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.